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In recent years, frequently happened commercial briberies in Chinese 
pharmaceutical industry have caused social universal attention. Over the past year, the 
event ‘GSK (the British pharmaceutical giant GlaxoSmithKline) bribery scandal in 
China’ has brought the issue back to public view. It’s well known that commercial 
briberies, as kind of anti-competitive conduct, seriously disrupt economic order and 
consequently generate unfair competition. Likewise, commercial briberies in Chinese 
pharmaceutical industry inevitably lead to a range of problems, such as artificially 
high drug prices, official corruption, nervous relationship between doctors and 
patients, severely damaging interest of both individuals and the country. Therefore, 
the governance of commercial briberies has become a priority for national drug 
regulatory authorities. 
The issue of the commercial briberies is usually studied from four angles, namely 
political, economic, cultural and legal, aiming at the fundamental reasons and 
effective governance. By comparison, with the use of case study method, this article 
studies the GSK bribery scandal and searches for the root causes of commercial 
briberies from the perspective of sales process and sales activity environment towards 
public hospitals. After review of previous studies in this issue, this article detailedly 
introduces and seriously analyses the case of GSK bribery scandal in China with the 
theory of sales process and sales activity environment defects. According to the 
analysis of the problems based on the case, the author puts forward four suggestions, 
including perfecting the sales process, optimizing the internal environment, 
strengthening the external supervisions and improving the legal system, to better 
regulate the sales behavior of pharmaceutical enterprise, thus effectively govern the 
commercial briberies in pharmaceutical industry. 
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